Trial reportPloS one2019
Squamous differentiation portends poor prognosis in low and intermediate-risk endometrioid endometrial cancer.
Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The Molecular Pathology of Morules in Endometrial Carcinoma: Biological Significance and Clinical Implications.Pathology international · 2026Review
- Multifaceted role ofiScience · 2026Article
- The Proteomic Landscape ofCells · 2025Article
- Post-surgery recurrence predictors for stage I-II endometrial carcinoma: a retrospective observational study.Future oncology (London, England) · 2025Observational
- Application of ultrasound in combination with other methods in gynecological disease: artificial intelligence, surgery, and drugs.Frontiers in oncology · 2025Review
- Endometrial endometrioid adenocarcinoma with a malignant squamous component: is the unusual metastatic pattern unique of these tumors?Virchows Archiv : an international journal of pathology · 2024Article
- An ultrasound-based radiomics model for survival prediction in patients with endometrial cancer.Journal of medical ultrasonics (2001) · 2023Article
- Overall survival prediction models for gynecological endometrioid adenocarcinoma with squamous differentiation (GE-ASqD) using machine-learning algorithms.Scientific reports · 2023Article
- P16 Expression in Human Breast Carcinoma and its Relationship to Clinicopathological Parameters.Advanced biomedical research · 2023Article
- Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.PLoS genetics · 2021Article
- The impact of Ki-67 index, squamous differentiation, and several clinicopathologic parameters on the recurrence of low and intermediate-risk endometrial cancer.Bosnian journal of basic medical sciences · 2021Article
- A 4-Gene Signature Associated With Recurrence in Low- and Intermediate-Risk Endometrial Cancer.Frontiers in oncology · 2021Article
- Immunohistochemical expression of PAX-8 in Sudanese patients diagnosed with malignant female reproductive tract tumors.BMC research notes · 2020Article
- Clinicopathological Prognostic Parameters of Endometrioid Endometrial Carcinomas.Current health sciences journalArticle
- The Potential Value of Ki-67 in Prognostic Classification in Early Low-Risk Endometrial Cancer.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial cancer presents well-defined risk factors: myometrial invasion, histological subtype, tumor grade, lymphovascular space invasion (LVSI). Some low and intermediate-risk endometrioid endometrial cancer patients exhibited unexpected outcomes. This study aimed to investigate other clinical-pathological factors that might influence the recurrence rates of patients diagnosed with low and intermediate-risk endometrioid endometrial cancer.
methodsA case-control study from a cohort retrospective of 196 patients diagnosed with low and intermediate-risk endometrioid endometrial cancer at a single institution from 2009 to 2014 was conducted. Medical records were reviewed to compare clinical (race, smoking, menopause age, body mass index) and pathological (endometrioid vs endometrioid with squamous differentiation, tumor differentiation grade, tumor location, endocervical invasion, LVSI) features of patients with recurrence (case) and without recurrence (control) of disease. Three controls for each case were matched for age and staging.
resultsTwenty-one patients with recurrence were found (10.7%), of which 14 were stage IA, and 7 were stage IB. In accordance, 63 patients without recurrence were selected as controls. There were no significant differences in any clinical characteristics between cases and controls. Among pathological variables, presence of squamous differentiation (28.6% vs. 4.8%, p = 0.007), tumor differentiation grade 2 or 3 (57.1% vs. 30.2%, p = 0.037) and presence of endocervical invasion (28.6% vs. 12.7%, p = 0.103) were associated with disease recurrence on a univariate analysis. On multivariable analysis, only squamous differentiation was a significant risk factor for recurrence (p = 0.031).
conclusionOur data suggest that squamous differentiation may be an adverse prognostic factor in patients with low and intermediate-risk endometrioid endometrial cancer, that showed a 5.6-fold increased risk for recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.